InnoCare Pharma (HKSE:09969) Ending Cash Position : HK$0.0 Mil (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is InnoCare Pharma Ending Cash Position?

InnoCare Pharma's Ending Cash Position for the quarter that ended in Sep. 2023 was HK$0.0 Mil.

InnoCare Pharma's annual Ending Cash Position increased from Dec. 2020 (HK$2,727.5 Mil) to Dec. 2021 (HK$3,964.2 Mil) and increased from Dec. 2021 (HK$3,964.2 Mil) to Dec. 2022 (HK$4,667.9 Mil).

InnoCare Pharma Ending Cash Position Historical Data

The historical data trend for InnoCare Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Ending Cash Position Chart

InnoCare Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

1,773.90

2,727.54

3,964.19

4,667.85

InnoCare Pharma Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Ending Cash Position	Get a 7-Day Free Trial											-	-	-	-	-

InnoCare Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

InnoCare Pharma's Ending Cash Position for the fiscal year that ended in Dec. 2022 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	3615.346	+	1052.504
	=	4,667.9

InnoCare Pharma's Ending Cash Position for the quarter that ended in Sep. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	0	+	0
	=	0.0

InnoCare Pharma Ending Cash Position Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCare Pharma (HKSE:09969) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

33C:Germany 688428:China

Address

No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206

Website

https://www.innocarepharma.com

InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (HKSE:09969) Headlines

No Headlines